Zentalis Pharmaceuticals, Inc.
$4.03
▲
2.33%
2026-04-21 10:26:01
zentalis.com
NGM: ZNTL
Explore Zentalis Pharmaceuticals, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$301.33 M
Current Price
$4.03
52W High / Low
$6.95 / $1.13
Stock P/E
—
Book Value
$3.13
Dividend Yield
—
ROCE
-57.45%
ROE
-49.54%
Face Value
—
EPS
$-1.91
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
106
Beta
1.66
Debt / Equity
18.3
Current Ratio
6.93
Quick Ratio
6.93
Forward P/E
-3.9
Price / Sales
—
Enterprise Value
$262.54 M
EV / EBITDA
-1.87
EV / Revenue
—
Rating
Buy
Target Price
$5.81
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | ADC Therapeutics SA | $4.25 | — | $543.75 M | — | -42.38% | 73.43% | $4.98 / $1.13 | $-1.48 |
| 2. | Passage Bio, Inc. | $6.25 | — | $37.44 M | — | -110.08% | -1.14% | $20 / $5.12 | $5.89 |
| 3. | Xilio Therapeutics, Inc. | $8.45 | — | $49.46 M | — | -42.66% | -1.33% | $16.52 / $6.47 | $7.79 |
| 4. | Definium Therapeutics, Inc. | $23.18 | — | $2.26 B | — | -44.54% | -64.06% | $23.41 / $5.36 | $3.36 |
| 5. | Cyclerion Therapeutics, Inc. | $3 | — | $13.08 M | — | -40.99% | -39.34% | $8.48 / $1.03 | $2.38 |
| 6. | IDEAYA Biosciences, Inc. | $33.6 | — | $2.95 B | — | -15.17% | -10.92% | $39.28 / $16.07 | $11.65 |
| 7. | Unicycive Therapeutics, Inc. | $7.43 | — | $177.17 M | — | -97.75% | -1.41% | $11 / $3.71 | $1.36 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M | 26.86 M | — |
| Operating Profit | -37.39 M | -33.73 M | -36.06 M | -37.83 M | -46.11 M | — |
| Net Profit | -35.22 M | -26.69 M | -26.87 M | -48.28 M | -47.47 M | — |
| EPS in Rs | -0.5 | -0.38 | -0.38 | -0.68 | -0.67 | -0.56 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 0 M | 67.42 M | 0 M | 0 M |
| Operating Profit | -145.01 M | -187.46 M | -253.94 M | -227.29 M |
| Net Profit | -137.06 M | -165.84 M | -292.19 M | -236.81 M |
| EPS in Rs | -1.93 | -2.34 | -4.12 | -3.34 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 288.97 M | 430.34 M | 551.69 M | 539.31 M |
| Total Liabilities | 72.76 M | 93.15 M | 114.3 M | 105.29 M |
| Equity | 216.2 M | 337.19 M | 437.28 M | 433.8 M |
| Current Assets | 253.19 M | 386.07 M | 496.72 M | 451.93 M |
| Current Liabilities | 36.56 M | 52.73 M | 69.37 M | 56.65 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -125.25 M | -170.86 M | -207.82 M | -163.75 M |
| Investing CF | 131.62 M | 176.56 M | -44.46 M | -114.18 M |
| Financing CF | -4.28 M | 0.11 M | 237.3 M | 261.04 M |
| Free CF | -125.25 M | -171.08 M | -208.41 M | -166.3 M |
| Capex | — | -0.22 M | -0.58 M | -2.55 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | — | — | — | — |
| Earnings Growth % | 43.24% | -23.39% | — | — |
| Profit Margin % | -245.96% | — | — | — |
| Operating Margin % | -278.02% | — | — | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | -276.11% | — | — | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.